People · Operator
Named in public records as an officer, director or promoter · active 2024–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AirNexis Therapeutics, Inc. | — | Biotechnology | Series C | $62.0M | $309.0M | 2026 |
| Renasant Bio, Inc. | — | Biotechnology | Series B | $55.5M | $143.9M | 2024 |
Evan Caplan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Evan Caplan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| Jill Carroll | 1 | 4 |
| Colin Walsh | 1 | 3 |
| Maria Fardis | 1 | 3 |
| June Lee | 1 | 3 |
| Anna Chen | 1 | 3 |
| Deborah Palestrant | 1 | 3 |
| Anna French | 1 | 3 |
| Emily Conley | 1 | 2 |
| Natalie Holles | 1 | 2 |
| Thomas Gustafson | 1 | 1 |
| James Li | 1 | 1 |
| Charlotte McKee | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.